Recombinant Human CD47 Protein, Fc Tag (HPLC-verified), 100µg

Background
Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. 

Source
Recombinant Human CD47, Fc Tag(CD7-H5256) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Pro 139 (Accession # Q08722-3).
Predicted N-terminus: Gln 19

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 40.4 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-Mals.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Checkpoint inhibition in hematologic malignancies"
Tsumura, Levis, Tuscano
Front Oncol (2023) 13, 1288172
(2) "CpG-Conjugated Silver Nanoparticles as a Multifunctional Nanomedicine to Promote Macrophage Efferocytosis and Repolarization for Atherosclerosis Therapy"
Tang, Wang, Guo et al
ACS Appl Mater Interfaces (2023)
(3) "Impaired Efferocytosis Enables Apoptotic Osteoblasts to Escape Osteoimmune Surveillance During Aging"
Xu, Xie, Shen et al
Adv Sci (Weinh) (2023)
Showing 1-3 of 2544 papers.

Citations

(1) "Therapeutic cd47 antibodies"
Authors: Manning Pamela T, et al.
Journal: US20180142019A1 2018
Application: SPR
(2) "A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety"
Authors: Yu XY, et al.
Journal: Biochimie 2018
Application: ELISA